The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

(2020) Kris V. Kowdley et al.   JOURNAL OF HEPATOLOGY

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

(2020) Ping An et al.   LIVER INTERNATIONAL

A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA

(2020) G.M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC

(2019) Michael Trauner et al.   HEPATOLOGY

NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter

(2019) James H. Tabibian et al.   JOURNAL OF HEPATOLOGY

Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis

(2019) Jessica R. Allegretti et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

(2019) Kate D. Lynch et al.   Clinical Gastroenterology and Hepatology

Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature

(2019) Christopher L. Bowlus et al.   JOURNAL OF AUTOIMMUNITY

Precision Medicine in Primary Sclerosing Cholangitis

(2019) James B Maurice et al.   Journal of Digestive Diseases

LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment

(2019) PD Dr. Schattenberg Jörn et al.   JOURNAL OF HEPATOLOGY

GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial

(2019) George Dalekos et al.   JOURNAL OF HEPATOLOGY

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

(2019) Maren H. Harms et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study

(2019) John E. Eaton et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis

(2019) Michael Huw Chapman et al.   GUT

Direct and Indirect Effects of FGF15 and FGF19 on Liver Fibrosis Development

(2019) J D Schumacher et al.   HEPATOLOGY

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

(2019) Michael Trauner et al.   Lancet Gastroenterology & Hepatology

Drug Therapies for Chronic Cholestatic Liver Diseases

(2019) Martin Wagner et al.   Annual Review of Pharmacology and Toxicology

Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies

(2019) Alessio Gerussi et al.   Annals of Hepatology

Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis

(2019) Christopher L. Bowlus et al.   Clinical Gastroenterology and Hepatology

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

(2018) B. Christensen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Primary biliary cholangitis: Old and novel therapy

(2018) Annarosa Floreani et al.   European Journal of Internal Medicine

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines

(2018) Gideon M Hirschfield et al.   GUT

Na+ -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice

(2018) Davor Slijepcevic et al.   HEPATOLOGY

Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial

(2018) Amardeep Khanna et al.   HEPATOLOGY

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

(2018) Kris V. Kowdley et al.   HEPATOLOGY

Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study

(2018) C. Schramm et al.   JOURNAL OF HEPATOLOGY

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice

(2018) Maria Eugenia Guicciardi et al.   JOURNAL OF HEPATOLOGY

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

(2018) Christophe Corpechot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA

(2018) Weijia Duan et al.   REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease

(2018) Andrew J. Muir et al.   HEPATOLOGY

Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study

(2018)   Journal of Gastrointestinal and Liver Diseases

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French–Spanish experience

(2018) Sara Lemoinne et al.   Clinics and Research in Hepatology and Gastroenterology

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial

(2018) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

(2017) Naoki Ikenaga et al.   GUT

Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis

(2017) David N. Assis et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

24- Nor ursodeoxycholic acid in patients with primary sclerosing cholangitis: A new “urso saga” on the horizon?

(2017) Olivier Chazouillères   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

(2017) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

nor Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

(2017) Peter Fickert et al.   JOURNAL OF HEPATOLOGY

Primary sclerosing cholangitis – a comprehensive review

(2017) Tom H. Karlsen et al.   JOURNAL OF HEPATOLOGY

Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline

(2017) Lars Aabakken et al.   JOURNAL OF HEPATOLOGY

Targeting the gut-liver axis in liver disease

(2017) Reiner Wiest et al.   JOURNAL OF HEPATOLOGY

Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol

(2017) Katherine Arndtz et al.   BMJ Open

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls

(2016) Martin Kummen et al.   GUT

Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study

(2016) Gideon M. Hirschfield et al.   HEPATOLOGY

A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study

(2016)   Journal of Gastrointestinal and Liver Diseases

Serum LYSYL Oxidase-Like-2 (SLOXL2) Levels Correlate with Disease Severity in Patients with Primary Sclerosing Cholangitis

(2016) A.J. Muir et al.   JOURNAL OF HEPATOLOGY

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes

(2015) A. C. Cheung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Bile Acids as Hormones: The FXR-FGF15/19 Pathway

(2015) Steven A. Kliewer et al.   DIGESTIVE DISEASES

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process

(2015) Cyriel Y. Ponsioen et al.   HEPATOLOGY

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2 -deficient mice

(2015) Mei Zhou et al.   HEPATOLOGY

Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis

(2015) Suguru Mizuno et al.   Journal of Hepato-Biliary-Pancreatic Sciences

New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond

(2015) Ulrich Beuers et al.   JOURNAL OF HEPATOLOGY

Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis

(2014) Chris J. Weston et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study

(2013) J. H. Tabibian et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid

(2013) Robert P Myers et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis

(2013) H. Tanaka et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy

(2013) Chen-Yen Yang et al.   HEPATOLOGY

PPARγ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis

(2013) Yusuke Nozaki et al.   Medical Molecular Morphology

The biliary HCO3− umbrella

(2012) Ulrich Beuers et al.   CURRENT OPINION IN GASTROENTEROLOGY

Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid

(2012) Marco Carbone et al.   GASTROENTEROLOGY

Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent

(2012) Tomonori Aoyama et al.   HEPATOLOGY

The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study

(2011) C. R. Martin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis

(2011) C. K. Triantos et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

(2011) Masanobu Tsuda et al.   HEPATOLOGY

Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms

(2010) Shi-Ying Cai et al.   JOURNAL OF LIPID RESEARCH

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

(2010) Vivian Barry-Hamilton et al.   NATURE MEDICINE

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

(2009) Keith D. Lindor et al.   HEPATOLOGY

Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials

(2009) Jian Shi et al.   HEPATOLOGY RESEARCH

PPAR-δ senses and orchestrates clearance of apoptotic cells to promote tolerance

(2009) Lata Mukundan et al.   NATURE MEDICINE

Minocycline in the Treatment of Patients With Primary Sclerosing Cholangitis: Results of a Pilot Study

(2008) Marina G Silveira et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY